B. Lydiard

发表

Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH‐A)

J. Endicott, M. Pollack, M. Otto, 2001, Depression and anxiety.

A 1 year double‐blind placebo‐controlled fixed dose study of sertraline in the treatment of obsessive‐compulsive disorder

J. Mendels, S. McElroy, K. Kobak, 1995, International clinical psychopharmacology.

Body dysmorphic disorder: symptom or syndrome.

K. Brady, B. Lydiard, L. Austin, 1994, The American journal of psychiatry.

Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.

R. Shrivastava, M. Fava, D. Sheehan, 2011, The Journal of clinical psychiatry.

Zolpidem Extended-Release Improves Sleep and Next-Day Symptoms in Comorbid Insomnia and Generalized Anxiety Disorder

R. Shrivastava, M. Fava, D. Sheehan, 2009, Journal of clinical psychopharmacology.

Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders.

S. Stahl, J. Zajecka, P. Ninan, 2000, Archives of general psychiatry.

L-methylfolate augmentation of selective serotonin reuptake inhibitors (SSRIS) for major depressive disorder: Results of two randomized, double-blind trials

S. Zisook, J. Alpert, L. Baer, 2011, European psychiatry.

Bipolar Affective Disorder and Substance Abuse

K. Brady, B. Lydiard, 1992, Journal of clinical psychopharmacology.

The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist, abecarnil (ZK 112-119), in generalized anxiety disorder.

S. Woods, J. Ballenger, B. Lydiard, 1992, Advances in biochemical psychopharmacology.

PHARMACOLOGIC AND PHARMACOKINETIC ASPECTS OF FGIDS 1423 Preclinical Pharmacology , Pharmacokinetics , and Toxicology Required for Novel Therapeutic Agents

B. Lydiard, J. Tack, F. Ponti, 2022 .